ライフサイエンスコーパス: lidocaine

1 local anesthesia (0.5% L-bupivacaine and 1% lidocaine).

2 idocaine, and 0.605 for 1% preservative-free lidocaine.

3 the superficial layers we topically applied lidocaine.

4 FVEP was unaltered by lidocaine.

5 gent current acts as a natural antagonist of lidocaine.

6 ine release in IM-treated rats receiving RVM lidocaine.

7 se 3 but not interleukin-6 was attenuated by lidocaine.

8 of MMC (0.2 mg/ml) and 1% preservative-free lidocaine.

9 osensitivity of Na(V)1.5 was approximated by lidocaine.

10 treatment with galanin, galanin antibody, or lidocaine.

11 following formalin injection with or without lidocaine.

12 l described stabilization of inactivation by lidocaine.

13 mutations to sensitize the sodium channel to lidocaine.

14 g/ml) was combined with 1% preservative-free lidocaine.

15 tive-free lidocaine, or 1% preservative-free lidocaine.

16 both enhanced and speeded in the presence of lidocaine.

17 posure to bupivacaine (0.0005, 0.005, 1 mM), lidocaine (0.002, 0.02, 4 mM) and ropivacaine (0.0007, 0

18 0 to 6.3; P=0.16); and for amiodarone versus lidocaine, 0.7 percentage points (95% CI, -3.2 to 4.7; P

19 08F in DIII-S4) identified in a rare case of lidocaine (1 mg/kg)-induced Brugada syndrome.

20 uM, respectively) than ranolazine (7.8 uM), lidocaine (133.5 uM), and lacosamide (158.5 uM).

21 0.07 microM) than ranolazine (16 microM) and lidocaine (17 microM).

22 ollowing formalin injection, with or without lidocaine; (2) application of lidocaine in the left scia

23 Lidocaine (5 mg/L), flunixin (8 mg/L) and morphine (48 m

24 d adenosine, lidocaine, and Mg/adenosine and lidocaine (5.7 mL O2/min/kg [95% CI, 4.7-6.8] to 4.9 mL

25 were randomly assigned to amiodarone (974), lidocaine (993), or placebo (1059); of those, 24.4%, 23.

26 The effects of lidocaine (a nonselective ion-channel inhibitor), P2X-pu

27 We used lidocaine, a local anesthetic and antiarrhythmic drug, t

28 First, the effect of lidocaine, a local anesthetic used for human skin biopsy

29 This isoflurane effect was attenuated by lidocaine, a local anesthetic with anti-inflammatory pro

30 y rapid pacing in cocultures; treatment with lidocaine, a Na(+) channel blocker, significantly decrea

31 We conclude that carbamazepine and lidocaine access the sodium channel in similar ways and

32 l-volume 7.5% NaCl adenocaine (adenosine and lidocaine, adenocaine) and Mg on hypotensive resuscitati

33 0.39, 95% confidence interval 0.21-0.71) and lidocaine (adjusted hazard ratio 0.72, 95% confidence in

34 (adjusted odds ratio, 3.4; 95% CI, 2.9-4.0), lidocaine (adjusted odds ratio, 0.2; 95% CI, 0.2-0.2), a

35 o, 0.94 [95% CI, 0.66-1.32]) or intraosseous lidocaine (adjusted risk ratio, 1.03 [95% CI, 0.74-1.44]

36 nce, 5.5% [95% CI, 1.5-9.5]) and intravenous lidocaine (adjusted risk ratio, 1.21 [95% CI, 1.02-1.45]

37 Results demonstrated that lidocaine administration did not prevent the hypersensit

38 ugs and provide a mechanism for benefit from lidocaine administration in clinical acquired long QT sy

39 or determinants of the voltage dependence of lidocaine affinity.

40 of 7.5% NaCl with adenocaine (adenosine and lidocaine, AL) and AL with Mg (ALM) on fluid requirement

41 ections of glucocorticoids plus lidocaine or lidocaine alone.

42 nefit as compared with epidural injection of lidocaine alone.

43 n the glucocorticoid-lidocaine group and the lidocaine-alone group, -1.0 points; 95% confidence inter

44 A dose of 10 micromol/L lidocaine also caused a more negative shift of steady-st

45 Responders to intravenous lidocaine also had significantly greater mean primary so

46 d adenosine, lidocaine, and Mg/adenosine and lidocaine also had significantly lower blood lactate (7.

47 We found that lidocaine also has little or no effect when applied intr

48 Lidocaine, an agent with rapid dissociation kinetics, ha

49 anced viability is eliminated by introducing lidocaine, an ATPase inhibitor.

50 However, ionized ranolazine and charged lidocaine analog (QX-314) failed to block mechanosensiti

51 or by the internal dialysis of low doses of lidocaine analog QX-314.

52 ality of anesthesia than does combination 2% lidocaine and 0.5% bupivacaine in patients undergoing vi

53 However, both MMC + 1% preservative-free lidocaine and 1% preservative-free lidocaine were more c

54 d potential (FVEP) also were recorded before lidocaine and at relevant times afterwards.

55 A homology model for how lidocaine and benzocaine bind in the closed and open/ina

56 esidue permits clear separation of action of lidocaine and benzocaine into 2 components that can be r

57 lidocaine, bupivacaine, or a combination of lidocaine and bupivacaine.

58 By applying lidocaine and measuring the gating currents, we demonstr

59 e IV bolus of 4 mL/kg 7.5% NaCl + adenosine, lidocaine and Mg (n = 8) or 4 mL/kg 7.5% NaCl (n = 8) at

60 tated by an electrostatic attraction between lidocaine and pi electrons of the aromatic rings of thes

61 d forearm by an anesthetic cream (containing lidocaine and prilocaine) on one of the 2 d, and a place

62 (iii) the analysis of the local anesthetics, lidocaine and prilocaine, in a gel and a cream.

63 The pure Na(+) channel blocker lidocaine and the antianginal ranolazine were additional

64 targeted to the pore-region binding site of lidocaine and the external binding site of aryl sulfonam

65 or MMC, 0.612 for MMC + 1% preservative-free lidocaine, and 0.605 for 1% preservative-free lidocaine.

66 for those who received radiocolloid plus 1% lidocaine, and 1.6 (1.3) for those who received radiocol

67 In all, 16 (4.1%) amiodarone, 11 (3.1%) lidocaine, and 6 (1.9%) placebo-treated patients survive

68 care, 97% for sodium bicarbonate, 90% for 1% lidocaine, and 90% for sodium bicarbonate plus 1% lidoca

69 tetrakis(4-chlorophenyl)borate, metergoline, lidocaine, and bromhexine.

70 njections of the cationic anesthetic QX-314, lidocaine, and capsaicin, delays the maturation of both

71 M carbamazepine, suggesting that lacosamide, lidocaine, and carbamazepine all bind to the same site.

72 Low-dose vaginal estrogen, lidocaine, and dehydroepiandrosterone may also be consid

73 ted by membrane repolarization, inhibited by lidocaine, and enhanced by a peptide-mimetic of the beta

74 ation, treatment with 7.5% NaCl + adenosine, lidocaine, and Mg generated significantly higher mean ar

75 translate small-volume 7.5% NaCl adenosine, lidocaine, and Mg hypotensive fluid resuscitation from t

76 n decreased in pigs that received adenosine, lidocaine, and Mg/adenosine and lidocaine (5.7 mL O2/min

77 Pigs that received adenosine, lidocaine, and Mg/adenosine and lidocaine also had signi

78 After 180 minutes, pigs in the adenosine, lidocaine, and Mg/adenosine and lidocaine group had thre

79 Higher cardiac index in the adenosine, lidocaine, and Mg/adenosine and lidocaine group was due

80 sely related to heart rate in the adenosine, lidocaine, and Mg/adenosine and lidocaine group.

81 me resuscitation with 7.5% NaCl + adenosine, lidocaine, and Mg/adenosine and lidocaine provided super

82 nd trial, we compared parenteral amiodarone, lidocaine, and saline placebo, along with standard care,

83 sis of verapamil, citalopram, amitriptyline, lidocaine, and sunitinib in dried blood spots.

84 ct no-talking policy, use of subconjunctival lidocaine, and topical antibiotic use were not statistic

85 flammatory agents, gabapentinoids, tramadol, lidocaine, and/or the N-methyl-d-aspartate class of glut

86 tly increased BP more than the group without lidocaine; and (4) there was delayed significant BP incr

87 the PVN were inhibited with intraparenchymal lidocaine, AngII-induced sodium ingestion was exaggerate

88 common mouthwash comprising diphenhydramine-lidocaine-antacid is also widely used.

89 dose of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash compared with a single dose

90 group, by 11.7 points in the diphenhydramine-lidocaine-antacid mouthwash group, and by 8.7 points in

91 group and no patients in the diphenhydramine-lidocaine-antacid mouthwash group.

92 use of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo significantly red

93 % CI, 0.1-5.9; P = .004) for diphenhydramine-lidocaine-antacid mouthwash vs placebo.

94 occurred in 3 patients (4%); diphenhydramine-lidocaine-antacid mouthwash, 3 (4%); and placebo, 2 (2%)

95 /5 mL water); 91 patients to diphenhydramine-lidocaine-antacid; and 92 patients to placebo.

96 The local anesthetic lidocaine appears to be able to access its binding site

97 ilaterally; (3) formalin injection following lidocaine application significantly increased BP more th

98 Thus, higher doses of lidocaine are aversive to uninjured animals, but disbudd

99 and rapid recovery, whereas mepivacaine and lidocaine are suitable for longer procedures.

100 f mitomycin C (MMC) and 1% preservative-free lidocaine (as an anesthetic) has gained popularity for i

101 times after blockade of axon transport with lidocaine at either the retrobulbar level (2 muL, 40 mug

102 esuscitation and 0.9% NaCl +/- adenosine and lidocaine at infusion of shed blood.

103 eiving epinephrine, vasopressin, amiodarone, lidocaine, atropine, bicarbonate, calcium, magnesium, an

104 materials formed via a chemical reaction of lidocaine base with a series of acids characterized by a

105 randomized to receive standard of care (SOC) lidocaine-based anesthesia and the other eye received co

106 ed by open-channel blockers, suggesting that lidocaine binding is favored by inactivation but prevent

107 shows that the residue N395 is critical for lidocaine binding to Nav1.7 and suggests that the respon

108 The results suggest that lidocaine binding to the channel enhances PF-05089771 in

109 Previous studies have shown that lidocaine binding to the pore domain causes a decrease i

110 example, the local anesthetics ambroxol and lidocaine block both Na(V)1.7 and NaChBac but affect act

111 These mutations eliminated use-dependent lidocaine block with no effect on tonic/rested state blo

112 We studied lidocaine blockade of I(Na) generated by wild-type and V

113 ationic lidocaine derivative QX-314 (N-ethyl-lidocaine) blocks effectively when applied internally wi

114 Following CSAR inhibition by epicardial lidocaine, blood pressure, HR, LVSP, dp/dt, LVEDP and ES

115 ndard deviation) of sensory blockade for the lidocaine, bupivacaine, and combination groups were 2.14

116 tandard deviation) of motor blockade for the lidocaine, bupivacaine, and combination groups were 3.04

117 d on the peribulbar injection they received: lidocaine, bupivacaine, or a combination of lidocaine an

118 als, comparable in magnitude to infusions of lidocaine, but with a slower onset and longer duration.

119 ous clinically used drugs including Demerol, lidocaine, capecitabine, and CPT-11 are hydrolyzed by th

120 omfortable intercourse after applying liquid lidocaine compresses to the vulvar vestibule before pene

121 ficant differences in cytotoxicity comparing lidocaine-containing solutions were observed.

122 re conditioned to associate the effects of a lidocaine cornual nerve block with the location and patt

123 1 fashion to receive the standard topical 4% lidocaine cream and injection of [(99m)Tc]Tc-sulfur coll

124 In constant 100 mum lidocaine, current-clamped Purkinje cells continued to f

125 CSAR inhibition by epicardial lidocaine decreased cardiac contractility to a greater e

126 ocol was further applied to oxidize the drug Lidocaine, demonstrating the potential utility of the de

127 Similarly, the beta4 peptide reduced lidocaine-dependent suppression of spiking in CA3 neuron

128 In contrast, the cationic lidocaine derivative QX-314 (N-ethyl-lidocaine) blocks e

129 n neuronal entry of the membrane-impermeable lidocaine derivative QX-314, leading to TLR5-dependent b

130 ux across skin-in combination with QX-314, a lidocaine derivative that has relative difficulty penetr

131 l interaction between the surfactant and the lidocaine derivative, not a systemic effect.

132 factants, and also was achieved with another lidocaine derivative, QX-222.

133 We note that lidocaine did not inhibit MMC cytotoxicity and exhibited

134 versible inactivation of the IP nucleus with lidocaine during conditioning evoked a complete disappea

135 ons of volatile anesthetics and subcutaneous lidocaine efficacy have been attributed in part to melan

136 ion potential clamp experiments suggest that lidocaine eliminates virtually all inward current elicit

137 -dependent inhibition and speeds recovery of lidocaine-engaged channels.

138 The results show that lidocaine enhances the degree and rate of inhibition of

139 in a 1:2 ratio to receive (1) an intra-oral lidocaine-epinephrine injection with buffered saline nas

140 cyclic aromatic hydrocarbons, angiotensin I, lidocaine, ferrocene, diesel, and rosemary oils were use

141 ertion or intercourse, all patients received lidocaine for 2 months in an open-label trial.

142 PSI cartridge was applied to the analysis of lidocaine from a paper tip using different solvent mixtu

143 ent solvent mixtures, and to the analysis of lidocaine from a serum sample.

144 Discomfort was significantly lower in the lidocaine gel group (P = .01).

145 Premedication with 4% lidocaine gel significantly reduced discomfort during sc

146 ion with acetaminophen, ibuprofen, and/or 4% lidocaine gel.

147 Intravenous lidocaine given for 7-10 days led to improvement in 90%

148 3.4 (5.1) for the sodium bicarbonate plus 1% lidocaine group (p<0.0001).

149 aine, and 90% for sodium bicarbonate plus 1% lidocaine group (p=0.56).

150 bupivacaine group compared with 23.3% in the lidocaine group and 30% in the combination group (P = 0.

151 treatment effect between the glucocorticoid-lidocaine group and the lidocaine-alone group, -1.0 poin

152 e adenosine, lidocaine, and Mg/adenosine and lidocaine group had three-fold higher urinary output (2.

153 e adenosine, lidocaine, and Mg/adenosine and lidocaine group was due to a two-fold increase in stroke

154 oup, 115.83+/-34.49 minutes, and that of the lidocaine group, 94.17+/-49.86 minutes (P < 0.001).

155 dium bicarbonate group, 4.6 (4.5) for the 1% lidocaine group, and 3.4 (5.1) for the sodium bicarbonat

156 e adenosine, lidocaine, and Mg/adenosine and lidocaine group.

157 VEDP and ESPVR decreased in CHF rats whereas lidocaine had little effect in sham rats, indicating tha

158 The anti-arrhythmic drug lidocaine has been shown to have a lower affinity for bl

159 A lidocaine HCl (Xylocaine) injection on the midline at th

160 quid doses of diphenhydramine hydrochloride, lidocaine hydrochloride, diazepam, and fluoxetine hydroc

161 The decreased preload by lidocaine in CHF rats may be due to a reduction in perip

162 drug administration route for amiodarone or lidocaine in comparison with placebo during out-of-hospi

163 ay implicate a possible therapeutic role for lidocaine in decreasing the inappropriate activation, po

164 lates inflammatory processes, the effects of lidocaine in sepsis are still unknown.

165 ith or without lidocaine; (2) application of lidocaine in the left sciatic nerve alone significantly

166 Intrathecal lidocaine in the lithotomy position carries a significan

167 ork activity in the chick embryo by infusing lidocaine in vivo triggers synaptic scaling in spinal mo

168 Furthermore, lidocaine inactivation (0.4 mul, 4%) studies demonstrate

169 , consistent with state-dependent binding by lidocaine increasing the fraction of channels presenting

170 We report the first case of lidocaine-induced Brugada electrocardiogram phenotype.

171 sumatriptan or alphaCGRP(8-37) abolished RVM lidocaine-induced CPP in IM-treated rats.

172 In rats having learned the water-maze task, lidocaine-induced inactivation of the ReRh right before

173 ions were not correlated with the respective lidocaine-induced slow recovery after short depolarizati

174 ignificantly correlated with the kinetics of lidocaine-induced slow recovery.

175 oscillations were reduced after intraseptal lidocaine infusions in rats.

176 depolarization and antagonized use-dependent lidocaine inhibition of fast-inactivated sodium channels

177 We therefore recorded lidocaine inhibition of voltage-clamped, tetrodotoxin-se

178 Our observation of reduced lidocaine inhibition on Nav1.7-N395K shows that the resi

179 th a site-3 toxin, anemone toxin II, reduced lidocaine inhibition; this effect was largely occluded b

180 Here, we show that lidocaine inhibits TRPV1 channels expressed in Xenopus l

181 local anaesthesia (0.5% L-bupivacaine and 1% lidocaine injected subcutaneously) or regional (brachial

182 Lidocaine injection caused rapid (retrobulbar ~10 minute

183 tive responses, mediated in part by TTX- and lidocaine-insensitive channels, were observed in most ce

184 These effects are blocked by infusions of lidocaine into the nucleus tractus solitarii (NTS) and b

185 P = 0.017] and the absence of intraoperative lidocaine intravenous perfusion (odds ratio: 0.182, 95%

186 Systemic lidocaine is anti-inflammatory but is effective only in

187 Lidocaine is generally considered much less cardiotoxic

188 input in the initial healing period and (b) lidocaine is ineffective at preventing long-term spinal

189 ation who survive 3 hrs, amiodarone, but not lidocaine, is associated with an increased risk of death

190 ted to the Na(+) channel-blocking anesthetic lidocaine, is used to treat LQT3 patients.

191 Intratracheal lidocaine, iso-PPADS, and TRPV4 genetic deficiency prote

192 After adjustment for confounders, both 2% lidocaine jelly (odds ratio [OR], 11.28; 95% CI, 3.39-37

193 Use of lidocaine jelly or Tetravisc may increase the risk of en

194 Infusion of lidocaine (LIDO) or vehicle had no effect on the neuroen

195 s are targeted by local anaesthetics such as lidocaine (lignocaine), some patients do not respond to

196 ized potentials, raising the question of how lidocaine-like compounds affect neurons with resurgent N

197 Although the local anesthetic lidocaine modulates inflammatory processes, the effects

198 Unilateral microinjections of lidocaine, muscimol, or glutamate antagonists into the p

199 Patients received lidocaine (n = 664, 59.0%), amiodarone (n = 50, 4.4%), b

200 zed to receive either a placebo (n = 7) or a lidocaine (n = 7) bolus (1.5 mg/kg), followed by continu

201 taining either sodium bicarbonate (n=35), 1% lidocaine (n=35), or sodium bicarbonate and 1% lidocaine

202 docaine (n=35), or sodium bicarbonate and 1% lidocaine (n=35).

203 c pain (ketamine, gabapentin, clonidine, and lidocaine), nociceptive pain (ketoprofen, baclofen, cycl

204 tate-dependent inhibition by PF-05089771 and lidocaine of human Nav1.7 channels expressed in human em

205 , epidural injection of glucocorticoids plus lidocaine offered minimal or no short-term benefit as co

206 l was conducted to investigate the effect of lidocaine on leukocyte recruitment in septic patients.

207 ring capacity, indicating a direct effect of lidocaine on signal transduction in neutrophils.

208 edge, no studies have analyzed the impact of lidocaine on the cytotoxic effects of MMC in this settin

209 We tested the effect of the LA lidocaine on the time course of recovery from short and

210 duced by a local VTA microinfusion of either lidocaine or (+/-)2-amino,5-phosphopentanoic acid (AP-5)

211 atly reduced by pretreatment with 300 microM lidocaine or 300 microM carbamazepine, suggesting that l

212 nistration of cocaine, intra-VTA infusion of lidocaine or AP-5 significantly diminished this effect.

213 larly, producing more potent inhibition than lidocaine or bupivacaine.

214 o effect on low-affinity tonic inhibition by lidocaine or its permanently charged derivative QX-314 a

215 epidural injections of glucocorticoids plus lidocaine or lidocaine alone.

216 esuscitation Outcomes Consortium Amiodarone, Lidocaine or Placebo Study), when stratified by the intr

217 porary cardiac pacing than did recipients of lidocaine or placebo.

218 inactivation using reagents that influenced (lidocaine) or spared (GABA receptor agonists) fibers of

219 (ketoprofen, baclofen, cyclobenzaprine, and lidocaine), or mixed pain (ketamine, gabapentin, diclofe

220 , diclofenac, baclofen, cyclobenzaprine, and lidocaine), or placebo.

221 ture of 0.2 mg/ml MMC + 1% preservative-free lidocaine, or 1% preservative-free lidocaine.

222 tivating neurons within the spinal cord with lidocaine, or cutting communication between the spinal c

223 omized, double-blind, to receive amiodarone, lidocaine, or placebo by paramedics.

224 was replicated among ALPS trial (Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest)

225 esuscitation Outcomes Consortium Amiodarone, Lidocaine, or Placebo Study trial.

226 miodarone arm of the ALPS trial (Amiodarone, Lidocaine, or Placebo Study).

227 eceived radiocolloid plus bicarbonate and 1% lidocaine (p<0.0001).

228 Day 0, disbudded calves tended to prefer the lidocaine-paired stimulus over the saline-paired one, su

229 On Day 20, sham calves avoided the lidocaine-paired stimulus, consistent with humans' exper

230 Day 0 sham calves did not avoid the lidocaine-paired stimulus, likely because they received

231 Furthermore, we also found that epicardial lidocaine paradoxically decreased left ventricular end-d

232 Furthermore, we found that epicardial lidocaine paradoxically decreased LV end-diastolic volum

233 tion for use and proposal as second line for lidocaine patches, capsaicin high-concentration patches,

234 and botulinum toxin A, and undetermined for lidocaine patches.

235 derate or high for all treatments apart from lidocaine patches; tolerability and safety, and values a

236 ced hypocontractility, parallel studies used lidocaine perfusion to abolish cardiac contraction.

237 Inactivation of the vHipp with lidocaine prevented the sustained, but not acute, antide

238 ition of the rmPFC by the local injection of lidocaine produced an increase in the amplitude of evoke

239 RVM lidocaine produced CPP, increased NAc c-Fos, and dopamin

240 + adenosine, lidocaine, and Mg/adenosine and lidocaine provided superior cardiovascular, acid-base, m

241 Treatment with lidocaine reduced net fluid secretion in the small intes

242 Concomitantly, lidocaine reduces maximum gating charge (Qmax) by 40% re

243 at concentrations (40-60 mumol/L) for which lidocaine remains specific for inactivated Na(+) channel

244 Users of lidocaine reported less pain during intercourse in the b

245 Overall, neither amiodarone nor lidocaine resulted in a significantly higher rate of sur

246 ylprednisolone) and three local anesthetics (lidocaine, ropivacaine, and bupivacaine) were added to s

247 n electrostatic barrier to ion permeation by lidocaine's charge.

248 on of the CA3 region of the hippocampus with lidocaine selectively eliminated source memory, suggesti

249 the hippocampus with bilateral infusions of lidocaine selectively eliminated the ability of rats to

250 These data suggest that lidocaine selectively inhibits chemokine-induced arrest

251 In addition, lidocaine sensitivity was dramatically reduced, which pr

252 Lidocaine shortened APD equally during acute and chronic

253 INa-L block with lidocaine shortened QTc and APD more at 6.5 hours than a

254 ipheral vascular resistance since epicardial lidocaine significantly lowered peripheral (renal) sympa

255 ateral injections of buffered and unbuffered lidocaine solutions were given before surgery to patient

256 r a bupivacaine lozenge (L-group, n = 51) or lidocaine spray (S-group, n = 42).

257 etic compared with standard treatment with a lidocaine spray before UGE.

258 A bupivacaine lozenge compared with a lidocaine spray proved to be a superior option as topica

259 LAs, especially ropivacaine and lidocaine, stimulated neutrophil NO generation, but in C

260 e affinity of the cardiac sodium channel for lidocaine such that the drug assumes Class IC characteri

261 d radiocolloid injection and pH-adjusted and lidocaine-supplemented formulations for patients undergo

262 or survival were greater after amiodarone or lidocaine than placebo, without increased risk of advers

263 nerve; however, in contrast to the effect of lidocaine, the application of QX-314 and capsaicin toget

264 from the literature, including the analgesic lidocaine, the Dess-Martin periodinane oxidation reagent

265 and eleclazine with the antiarrhythmic drug lidocaine, the prototype I (NaL) inhibitor ranolazine, a

266 terned spiking was induced by application of lidocaine to the DRG, thus pinpointing intermittent fail

267 Administration of lidocaine to the dura prevented activation of all neuron

268 with early breast cancer, the addition of 1% lidocaine to the radioisotope solution can improve patie

269 advanced cardiac life support algorithm for lidocaine toxicity as well as other lipid soluble drug i

270 sion therapy after prolonged and intractable lidocaine toxicity.

271 herapy for intractable cardiac arrest due to lidocaine toxicity.

272 sed to normokalaemic (n = 25, 14 hearts), or lidocaine-treated hypokalaemic (n = 8, five hearts) or n

273 arts), hypokalaemic (n = 8, five hearts), or lidocaine-treated normokalaemic (n = 8, five hearts) or

274 Lidocaine treatment abrogated chemokine-induced neutroph

275 tor phenotype were responders to intravenous lidocaine treatment compared with nonresponders.

276 onsecutive patients who received intravenous lidocaine treatment for painful DPN were screened.

277 dividuals with hereditary erythromelalgia to lidocaine treatment may be determined, at least in part,

278 responders and nonresponders to intravenous lidocaine treatment using quantitative sensory testing.

279 After open-label lidocaine use, 37 (90%) of 41 reported comfortable penet

280 acebo were 2.3% (-0.3, 4.8), P=0.08, and for lidocaine versus placebo 1.2% (-1.1, 3.6), P=0.30.

281 nce interval [CI], -0.4 to 7.0; P=0.08); for lidocaine versus placebo, 2.6 percentage points (95% CI,

282 The odds ratio of responding to intravenous lidocaine was 8.67 times greater (95% CI 1.4-53.8) for t

283 Local lidocaine was applied to the left sciatic nerve to block

284 control channel states during drug exposure, lidocaine was applied with rapid-solution exchange techn

285 Inhibition of Na currents by lidocaine was diminished by either the beta4 peptide or

286 seline, use-dependent inhibition of I(Na) by lidocaine was more pronounced in V232I+L1308F versus wil

287 .96, 95% confidence interval 1.21-3.16), but lidocaine was not at 30 days (adjusted hazard ratio 1.19

288 of NsVBa, whereas the local anesthetic drug lidocaine was shown to antagonize NsVBa without affectin

289 erned spiking was not induced by intradermal lidocaine, was independent of stimulus modality (mechani

290 tive-free lidocaine and 1% preservative-free lidocaine were more cytotoxic than MMC and PBS (P < 0.01

291 at of classic sodium channel inhibitors like lidocaine, which also bind with higher affinity to the i

292 nnels also bind exogenous compounds, such as lidocaine, which functionally stabilize inactivation.

293 e percent of patients preferred the buffered lidocaine with a scaled pain reduction of 0.9 (P = 0.000

294 Determine if raising the pH of 2% lidocaine with epinephrine 1:100 000 to a physiologic le

295 Buffering 2% lidocaine with epinephrine 1:100 000 with sodium bicarbo

296 ous injections of buffered and unbuffered 2% lidocaine with epinephrine 1:100 000.

297 al plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine) or local anesthesia (0.5% L-

298 B]) anaesthesia (0.5% L-bupivacaine and 1.5% lidocaine with epinephrine).

299 nesthesia, and defining the 'safest' dose of lidocaine with epinephrine.

300 t they traded off the short-term pain of the lidocaine with the longer-term analgesia provided.